Tech Company Financing Transactions
Omniose Funding Round
On 10/11/2022, Omniose secured $3.6 million in financing from National Institutes of Health.
Transaction Overview
Company Name
Announced On
10/11/2022
Transaction Type
Venture Equity
Amount
$3,600,000
Round
Undisclosed
Investors
National Institutes of Health (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the development of a Klebsiella pneumoniae vaccine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4340 Duncan Ave 202
St. Louis, MT 63110
USA
St. Louis, MT 63110
USA
Phone
Undisclosed
Website
Email Address
Overview
Omniose was founded in 2017 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes. The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo. Omniose has been awarded $4.6 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Cooke
Chief Scientific Officer
Christian Harding
Co-Founder
Mario Feldman
Co-Founder
Christine Szymanski
Browse more venture capital transactions:
Prev: 10/10/2022: Trendsi venture capital transaction
Next: 10/11/2022: OatFi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs